Background: Cerebral amyloid angiopathy (CAA) is classified as type 1 with capillary amyloid β (Aβ) or type 2 without capillary Aβ. While it is known that CAA activates complement, an inflammatory mediator, there is no information on the relationship between capillary Aβ and complement activation. Methods: We evaluated 34 autopsy brains, including 22 with CAA and 12 with other neurodegenerative diseases. We assessed the vascular density of CAA by analyzing the expression of complement (C1q, C3d, C6, C5b-9), macrophage scavenger receptor (MSR), and apolipoprotein E (ApoE). Results: Capillary immunostaining for C1q, C3d, MSR, and ApoE was identified almost exclusively in CAA-type1 brains. There was intense expression of C1q, C3d, MSR, and ApoE, as well as weaker expression of C5b-9 and C6 in the arteries/ arterioles of both CAA subtypes, but not in control brains. C5b-9 and C6 were preferentially expressed in arteries/arterioles with subcortical hemorrhage or cortical superficial siderosis. Triple immunofluorescence revealed that C1q, C3d, and ApoE were colocalized with Aβ in CAA brain capillaries. Conclusion: Complement, MSR, and ApoE were only coexpressed in the presence of Aβ accumulation in capillaries, suggesting a role for complement activation in the propagation of Aβ. Additionally, C5b-9 expression may be associated with hemorrhagic brain injury in CAA.

Keywords:
Alzheimer disease, Apolipoprotein E, Microglia, Perivascular drainage
1.
Charidimou A, Gang Q, Werring DJ: Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012; 83: 124–137.
2.
Nakata-Kudo Y, Mizuno T, Yamada K, Shiga K, Yoshikawa K, Mori S, Nishimura T, Nakajima K, Nakagawa M: Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord 2006; 22: 8–14.
3.
Attems J, Jellinger K, Thal DR, Van Nostrand W: Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2011; 37: 75–93.
4.
Thal DR, Ghebremedhin E, Rub U, Yamaguchi H, Del Tredici K, Braak H: Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002; 61: 282–293.
5.
Makela M, Paetau A, Polvikoski T, Myllykangas L, Tanskanen M: Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+). J Alzheimers Dis 2016; 49: 149–157.
6.
Eikelenboom P, Stam FC: Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol 1982; 57: 239–242.
7.
Webster S, Glabe C, Rogers J: Multivalent binding of complement protein C1Q to the amyloid beta-peptide (Aβ) promotes the nucleation phase of Aβ aggregation. Biochem Biophys Res Commun 1995; 217: 869–875.
8.
Shen Y, Sullivan T, Lee CM, Meri S, Shiosaki K, Lin CW: Induced expression of neuronal membrane attack complex and cell death by Alzheimer’s β-amyloid peptide. Brain Res 1998; 796: 187–197.
9.
Yang LB, Li R, Meri S, Rogers J, Shen Y: Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer’s disease. J Neurosci 2000; 20: 7505–7509.
10.
Akiyama H, McGeer PL: Brain microglia constitutively express β-2 integrins. J Neuroimmunol 1990; 30: 81–93.
11.
Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, et al: Complement activation by β-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992; 89: 10016–10020.
12.
McGeer EG, Yasojima K, Schwab C, McGeer PL: The pentraxins: possible role in Alzheimer’s disease and other innate inflammatory diseases. Neurobiol Aging 2001; 22: 843–848.
13.
Verbeek MM, Otte-Holler I, Veerhuis R, Ruiter DJ, De Waal RM: Distribution of A β-associated proteins in cerebrovascular amyloid of Alzheimer’s disease. Acta Neuropathol 1998; 96: 628–636.
14.
Tanskanen M, Lindsberg PJ, Tienari PJ, Polvikoski T, Sulkava R, Verkkoniemi A, Rastas S, Paetau A, Kiuru-Enari S: Cerebral amyloid angiopathy in a 95+ cohort: complement activation and apolipoprotein E (ApoE) genotype. Neuropathol Appl Neurobiol 2005; 31: 589–599.
15.
Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JA, Perry VH, Weller RO: Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 2008; 34: 131–144.
16.
Weller RO, Djuanda E, Yow HY, Carare RO: Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 2009; 117: 1–14.
17.
Weller RO, Hawkes CA, Kalaria RN, Werring DJ, Carare RO: White matter changes in dementia: role of impaired drainage of interstitial fluid. Brain Pathol 2015; 25: 63–78.
18.
Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M: A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 2012; 4: 147ra111.
19.
Nedergaard M: Neuroscience. Garbage truck of the brain. Science 2013; 340: 1529–1530.
20.
Thrane AS, Rangroo Thrane V, Nedergaard M: Drowning stars: reassessing the role of astrocytes in brain edema. Trends Neurosci 2014; 37: 620–628.
21.
Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV, Frangione B, Blennow K, Menard J, Zetterberg H, Wisniewski T, de Leon MJ: Clearance systems in the brain – implications for Alzheimer disease. Nat Rev Neurol 2015; 11: 457–470.
22.
Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, Neal JW, Love S, Nicoll JA, Boche D: Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization. Brain 2013; 136: 2677–2696.
23.
Fischer VW, Siddiqi A, Yusufaly Y: Altered angioarchitecture in selected areas of brains with Alzheimer’s disease. Acta Neuropathol 1990; 79: 672–679.
24.
Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT; National Institute on Aging; Alzheimer’s Association: National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 2012; 123: 1–11.
25.
Shen Y, Yang L, Li R: What does complement do in Alzheimer’s disease? Old molecules with new insights. Transl Neurodegener 2013; 2: 21.
26.
Zabel M, Schrag M, Crofton A, Tung S, Beaufond P, Van Ornam J, Dininni A, Vinters HV, Coppola G, Kirsch WM: A shift in microglial β-amyloid binding in Alzheimer’s disease is associated with cerebral amyloid angiopathy. Brain Pathol 2013; 23: 390–401.
27.
Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B: Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016; 352: 712–716.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.